- FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
- Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
- Guardant Health to Participate in Upcoming Investor Conferences
- Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
- Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
- FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
- Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
More ▼
Key statistics
On Tuesday, Guardant Health Inc (GH:NSQ) closed at 26.16, 65.46% above the 52 week low of 15.81 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.22 |
---|---|
High | 26.83 |
Low | 23.34 |
Bid | 25.17 |
Offer | 26.14 |
Previous close | 26.16 |
Average volume | 3.37m |
---|---|
Shares outstanding | 122.37m |
Free float | 116.82m |
P/E (TTM) | -- |
Market cap | 3.20bn USD |
EPS (TTM) | -3.92 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼